sur Aap Implantate AG (isin : DE0005066609)
Aap Implantate AG Reports Positive Sales Growth for Q2 and H1 2024
aap Implantate AG has announced significant sales growth for the second quarter (Q2) and first half (H1) of 2024. Q2 sales rose by 14% year-over-year (yoy), reaching EUR 3.3 million, primarily driven by a 44% growth in the EMEA region. H1/2024 sales increased by 10% compared to H1/2023, totaling EUR 6.4 million.
The company’s human clinical trial of its innovative antibacterial implant technology has recruited 200 patients. aap has applied to complete patient recruitment, with potential early completion of the 12-month follow-up phase.
Despite a 22% decline in North American sales due to first-quarter reorganization impacts, positive customer acquisition trends and a robust project pipeline offer optimism for recovery. Latin America and APAC regions also showed promising growth patterns.
R. H.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Aap Implantate AG